Eccogene is a clinical-stage biopharmaceutical company based in Shanghai focused on discovery and development of translational medicines for metabolic and immune-related diseases. Its pipeline targets metabolic indications including obesity, type 2 diabetes, NASH, and lipid disorders. Lead programs include ECC5004, a small-molecule GLP-1 receptor agonist for obesity and type 2 diabetes, and ECC4703, a THRβ full agonist for NASH and lipid disorders. The company also has ECC0509, a peripherally distributed SSAO/VAP-1 inhibitor, which is nearing completion of a Phase I clinical trial. Led by CEO Jingye Zhou, Eccogene intends to advance its clinical-stage metabolic pipeline using newly raised funds. The company positions itself to address unmet medical needs globally through translational medicine.

Total raised

$25M

Funding rounds

1

Latest round

Series B

Latest activity

Jun 2023